Highlights of weekly biotech stock moves

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $12.74 (21%) to $72.83 last week after at least two analysts raised their price targets on the stock and EMA's CHMP backed approval of an MAA for Lojuxta lomitapide. Canaccord's Salveen Richter and JPMorgan's Cory Kasimov cited progress with the launch of lomitapide for homozygous familial hypercholesterolemia (hoFH) in the U.S., where it is marketed as Juxtapid (see Analysts, A20).

Bavarian Nordic A/S (CSE:BAVA) was up DKK0.50 to DKK69.50 on Friday after EMA's CHMP issued a positive opinion recommending approval of an MAA for Imvanex smallpox vaccine. The company has been supplying the third-generation modified vaccinia Ankara (MVA) virus vaccine to the U.S. Strategic National Stockpile since 2010. The vaccine is in Phase III testing in the U.S. The stock was up DKK2.50 on the week...